124 filings
Page 3 of 7
8-K
jwf57je
16 Mar 23
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
4:09pm
8-K
7u9zu5y9
9 Jan 23
Regulation FD Disclosure
4:48pm
S-8
upwocxjsj0y4 y5jt7
9 Jan 23
Registration of securities for employees
4:14pm
8-K
59ibl0
5 Dec 22
Regulation FD Disclosure
7:39am
8-K
oc5y 24o6dw6350f3pz
2 Dec 22
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019
4:08pm
8-K
h1fbihje
9 Nov 22
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
4:03pm
8-K
ya1y9l6 lsfman6dp
11 Aug 22
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
4:10pm
8-K
sy4boyip lke6wx
10 Jun 22
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
wdhkh klv9
16 May 22
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
4:09pm
8-K
lt7nemn dkyy2jh2c53
12 May 22
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights
4:09pm
8-K
w6u9l2ou36m6r1
28 Apr 22
Other Events
4:20pm
424B5
miygi4uwmx jl03ah
26 Apr 22
Prospectus supplement for primary offering
4:02pm
424B5
r35h2slg x1nq6qjiad
25 Apr 22
Prospectus supplement for primary offering
4:03pm
8-K
p4m9kk7gzhl1s nyia
25 Apr 22
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
7:52am
8-K
1mn34ru21lbgpxeoq2
22 Apr 22
Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from
4:17pm